Opportunity to cure blindness of one session provided the payment of 850 thousand dollars
Opportunity to cure blindness of one session provided the payment of 850 thousand dollars
Spark Therapeutics has revealed a very high price for its new gene therapy for the blindness of Lucastorna, sparking controversy over the affordability of leading treatments, Sputnik said.
The company said the price of the treatment was 850,000 US dollars, making it the most expensive drug available on the market at all, according to the British Financial Times.
The company will receive 425,000 US dollars for each eye treated using the "Locastorna", the treatment, which has recently become the first approved gene therapy from the US Food and Drug Administration, and Marazzo said in an interview last month that Spark Believes that "the value of such treatment exceeds one million dollars."
The treatment involves the insertion of a healthy copy of a gene directly to the eye, where the gene stimulates the body to secrete a vital protein in the visual process. In clinical trials, the drug succeeded in restoring vision to some patients with severe visual impairment.
The company said it would participate in a scheme to take the risk of failure of treatment by returning part of its price to health insurance companies according to the effectiveness of treatment in the first 30-90 days, in addition to the continued effectiveness of treatment after 30 months.
Spark said she had prepared another plan that would allow the property to be sold directly to insurance companies and specialty pharmacies, instead of hospitals and treatment centers, which usually charge a large fee that would be prohibitively expensive in the case of expensive drugs such as Lucastrana.
Spark said government laws did not allow the property to be offered for sale under installment plans that help insurance companies and patients afford long-term costs.
Unlike traditional drugs that take months or years to reach the end result, these genetic treatments are used once to treat the disease from its source and repair the damaged DNA so that the body can treat itself.Opportunity to cure blindness of one session provided the payment of 850 thousand dollars
Spark Therapeutics has revealed a very high price for its new gene therapy for the blindness of Lucastorna, sparking controversy over the affordability of leading treatments, Sputnik said.
The company said the price of the treatment was 850,000 US dollars, making it the most expensive drug available on the market at all, according to the British Financial Times.
The company will receive 425,000 US dollars for each eye treated using the "Locastorna", the treatment, which has recently become the first approved gene therapy from the US Food and Drug Administration, and Marazzo said in an interview last month that Spark Believes that "the value of such treatment exceeds one million dollars."
The treatment involves the insertion of a healthy copy of a gene directly to the eye, where the gene stimulates the body to secrete a vital protein in the visual process. In clinical trials, the drug succeeded in restoring vision to some patients with severe visual impairment.
The company said it would participate in a scheme to take the risk of failure of treatment by returning part of its price to health insurance companies according to the effectiveness of treatment in the first 30-90 days, in addition to the continued effectiveness of treatment after 30 months.
Spark said she had prepared another plan that would allow the property to be sold directly to insurance companies and specialty pharmacies, instead of hospitals and treatment centers, which usually charge a large fee that would be prohibitively expensive in the case of expensive drugs such as Lucastrana.
Spark said government laws did not allow the property to be offered for sale under installment plans that help insurance companies and patients afford long-term costs.
Unlike traditional drugs that take months or years to reach the end result, these genetic treatments are used once to treat the disease from its source and repair the damaged DNA so that the body can treat itself.Opportunity to cure blindness of one session provided the payment of 850 thousand dollars
Spark Therapeutics has revealed a very high price for its new gene therapy for the blindness of Lucastorna, sparking controversy over the affordability of leading treatments, Sputnik said.
The company said the price of the treatment was 850,000 US dollars, making it the most expensive drug available on the market at all, according to the British Financial Times.
The company will receive 425,000 US dollars for each eye treated using the "Locastorna", the treatment, which has recently become the first approved gene therapy from the US Food and Drug Administration, and Marazzo said in an interview last month that Spark Believes that "the value of such treatment exceeds one million dollars."
The treatment involves the insertion of a healthy copy of a gene directly to the eye, where the gene stimulates the body to secrete a vital protein in the visual process. In clinical trials, the drug succeeded in restoring vision to some patients with severe visual impairment.
The company said it would participate in a scheme to take the risk of failure of treatment by returning part of its price to health insurance companies according to the effectiveness of treatment in the first 30-90 days, in addition to the continued effectiveness of treatment after 30 months.
Spark said she had prepared another plan that would allow the property to be sold directly to insurance companies and specialty pharmacies, instead of hospitals and treatment centers, which usually charge a large fee that would be prohibitively expensive in the case of expensive drugs such as Lucastrana.
Spark said government laws did not allow the property to be offered for sale under installment plans that help insurance companies and patients afford long-term costs.
Unlike traditional drugs that take months or years to reach the end result, these genetic treatments are used once to treat the disease from its source and repair the damaged DNA so that the body can treat itself.